Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
The US government paused all foreign assistance in January 2025. This abrupt decision affected the delivery of life-saving ...
Around the world, some 40 million people are living with HIV. And though progress in treatment means the infection isn’t the death sentence it once was, researchers have never been able to bring about ...
HIV was once a death sentence. Thanks to antiretroviral therapy, it’s now a chronic disease. But the daily treatment is for life. Without the drug, the virus rapidly rebounds. Scientists have long ...
People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus for certain participants in recent trials in Africa and Europe A digital ...
People infected with HIV must take antiretroviral drugs for life. But promising trials using engineered antibodies suggest that "functional cures" may be in reach. When you purchase through links on ...
Decades after its discovery, HIV continues to take lives and challenge global health systems. There are many challenges to combating HIV, including the complexity of developing a vaccine for a virus ...
In 1981, physicians in Los Angeles reported five young patients with Pneumocystis pneumonia, a rare lung infection later recognized as the first sign of HIV infection and a defining illness of AIDS.
In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly powerful antibody, called 04_A06, that is able to neutralize nearly all of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results